

**DRUG PLASMA LEVEL QUANTIFICATION BY LC-MS/MS | CATALOGUE 2023**

Service of Clinical Pharmacology - Laboratory PCL8 - CHUV- Lausanne

Prof. Laurent Decosterd, Dr Eva Choong Tel. 021 314 42 71 (Email: labo.pharmaco-clin@chuv.ch)

In case of **TDM clinical interpretation**: supplement 3.60 CHF / min (Tarmed 00.0141)

Tel: 021 314 25 00 or 021 314 14 04

Drugs	Trademark (examples)	TDM (1)	Drugs	Trademark (examples)	TDM (1)
ANTIRETROVIRALS (LA 1084, pts 144) - Analyses once a week (Wednesday to Friday)					
Abacavir	Ziagen, in Triumeq	C	Emtricitabine	Emtriva, in Descovy	C
Atazanavir	Reyataz	B	Etravirine	Intelence	B
Bictegravir	Biktarvy	B	Fostemsavir/Temsavir	Rukobia	C
Cabotegravir	Vocabria	B	Lamivudine	Trizivir, in Triumeq	C
Darunavir	Prezista	B	Maraviroc	Celsenti	B
Dolutegravir	Tivicay, in Triumeq	B	Nevirapine	Viramune	B
Doravirine	Pifeltro, in Delstrigo	B	Raltegravir	Isentress	B
Efavirenz	Stocrin	A	Rilpivirine	Edurant, Rekambys	B
Elvitegravir	Stribild	B	Tenofovir	Viread, in Descovy or Eviplera	B

ANTIVIRALS (LA 1084, pts 144) - Analyses twice a week (Tuesday, Friday)					
Aciclovir	Zovirax	B	Ribavirin ⁽³⁾	Copegus, Rebetol	B
Ganciclovir	Cymevene	B	Valaciclovir	Valtrex	B
Letermovir	Prevymis	C	Valganciclovir	Valcyte	B

ANTIPILEPTICS (LA 1069, pts 126) - Analyses every working day					
Brivaracetam	Briviact	B	Oxcarbazepine (OH-Oxcarbazepine)	Trileptal	B
Carbamazepine (+ CBZ-epoxide)	Tegretol	B	Perampanel	Fycompa	B
Eslicarbazepine	Zebinix	B	Pregabalin	Lyrica	C
Gabapentin	Neurotin	B	Rufinamide	Inovelon	B
Lacosamide	Vimpat	B	Topiramate	Topamax	B
Lamotrigine	Lamictal	B	Sulthiame	Ospolot	C
Levetiracetam	Keppra	B	Zonisamide	Zonegran	B

TARGETED ANTICANCER DRUGS (LA 1772, pts 126) - Analyses once a week (Monday, Tuesday)					
Abemaciclib	Verzenio	C	Olaparib	Lynparza	C
Alpelisib	Piqray	D	Osimertinib	Tagrisso	C
Asciminib	Scemblix	C	Palbociclib	Ibrance	D
Axitinib	Inlyta	C	Pazopanib	Votrient	C
Bosutinib	Bosulif	C	Ponatinib	Iclusig	D
Cobimetinib	Cotellic	D	Regorafenib (+ M2,M5)	Stivarga	D
Dabrafenib	Tafinlar	D	Ruxolitinib	Jakavi	D
Dasatinib	Sprycel	C	Sorafenib	Nexavar	C
Erlotinib	Tarceva	D	Sunitinib	Sutent	C
Gefitinib	Iressa	D	Tamoxifen / Endoxifen	Tamoxifen	B
Ibrutinib	Imbruvica	D	Trametinib	Mekinist	C
Imatinib	Glivec	A	Vemurafenib	Zelboraf	C
Nilotinib	Tasigna	C			

IMMUNOSUPPRESSIVE AGENTS (LA 1469 pts 135) AND CYTOSTATICS (LA 1772, pts 126) - Analyses once a week (Wednesday)					
6-Mercaptopurine (6-TGN, 6-MMP)	Puri-Nethol, Xaluprine	B	Abrocitinib	Cibinqo	D
6-Thioguanine (6-TGN)	Lanvis	B	Baricitinib	Olumiant	D
Azathioprine (6-TGN, 6-MMP)	Imurek	B	Fedratinib	Inrebic	D
<i>Asparaginase and Thiopurine S-methyltransferase (TPMT) activity</i>		B	Tofacitinib	Xeljanz	D
Mycophenolic acid (+ MPAG, AcMPAG)	CellCept, Myfortic	C	Upadacitinib	Rinvoq	D

MATERIAL FOR ALL ANALYSES : 4.9ml K-EDTA tubeAll pre-analytical information on : www.chuv.ch/analyses

Drugs	Trademark (examples)	TDM (1)	Drugs	Trademark (examples)	TDM (1)
ANTIBIOTICS (LA 1061, pts 166.5) - Analyses every working day (*or every other day)					
Amoxicillin	Clamoxyl	B	Doxycycline*	Vibramycin	D
Azithromycin*	Zithromax	C	Ertapenem	Invanz	B
Cefazolin*	Kefzol	B	Erythromycin*	Erythrocin	C
Cefepime	Maxipime	A	Flucloxacillin	Floxapen	B
Cefiderocol*	Fetcroja	D	Hydroxychloroquine*	Plaquenil	D
Ceftaroline*	Zinforo	D	Imipenem	Tienam	B
Ceftazidime	Fortam	B	Levofloxacin*	Tavanic	D
Ceftobiprole*	Zevtera	D	Linezolid*	Zyvoxid	B
Ceftolozane*	Zerbaxa	D	Meropenem	Meronem	B
Ceftriaxone	Rocephine	B	Metronidazole *	Flagyl	C
Cefuroxime*	Zinat	D	Oritavancin*	Tenkasi	C
Ciprofloxacin*	Ciproxine	C	Penicillin G (= benzylpenicillin)*	«Grünenthal»	C
Clarithromycin*	Klacid	C	Piperacillin	Tazobac	B
Clindamycin*	Dalacin	C	Rifampicin	Rimactan	C
Colistin (+ Colistin methanesulfonate)	Colimycine	B	Tigecyclin*	Tygacil	C
Daptomycin	Cubicin	B	Trimethoprim-Sulfamethoxazole*	Bactrim	D

ANTIFUNGAL DRUGS (LA 1077, pts 144) - Analyses twice a week (Monday and Thursday)					
Anidulafungin	Eraxis	B	Itraconazole / Hydroxy-itraconazole	Sporanox	B
Caspofungin	Cancidas	B	Posaconazole	Noxafil	B
Fluconazole	Diflucan	B	Voriconazole	Vfend	A
Isavuconazole	Cresemba	C			

ANTITUBERCULOSIS DRUGS (LA 1061, pts 166.5) - Analyses once a week (Thursday)					
Bedaquiline	Sirturo (EMA)	C	p-Aminosalicilic acid (PAS)	Granupas (EMA)	C
Cycloserine	Seromycin (FDA)	C	Pretomanid	Dovprela (EMA)	C
Clofazimine	Lamprene	C	Prothionamide		C
Delamanid (+metabolite DM6705)	Deltyba (EMA)	C	Pyrazinamide	in Rimstar	B
Ethambutol	Myambutol, in Rimstar	B	Rifabutin	Mycobutin	C
Isoniazid (+acetyl-isoniazid)	Rimactazid, in Rimstar	B	Rifampicin	Rimactan, in Rimstar	B
Levofloxacin: see Antibiotics		C	Rifapentine	Priftin (FDA)	C
Linezolid: see Antibiotics		C	Streptomycin		C
Moxifloxacin	Avalox	C	Sutezolid		C

ANTIPARASITIC (ANTIMALARIAL) DRUGS⁽⁴⁾ - Analyses on demand					
Amodiaquine (+Desethyl-amodiaquine)		C	Piperaquine	in Eurartesim (EMA)	C
Artemether (+Dihydroartemisinin, DHA)	in Riamet	C	Pyrimethamine	Daraprim	C
Artesunate (+DHA)	Artes.Amivas (EMA)	C	Pyronaridine		C
Chloroquine	Nivaquine	C	Quinine	Qualaquin (FDA)	C
Lumefantrine (+Desbutyl-lumefantrine)	in Riamet	C	Sulfadoxine		C
Mefloquine	Lariam	C	Hydroxychloroquine: see Antibiotics		C

OTHERS⁽⁴⁾ - Analyses on demand					
Levosimendan	Simdax	D	Lumacaftor	in Orkambi ⁽⁴⁾	D
Elexacaftor (+M23)	in Trikafta ⁽⁴⁾		Tezacaftor (+M1)	in Trikafta ⁽⁴⁾	D
lvacaftor (+M1)	in Orkambi, Trikafta ⁽⁴⁾	D			

MATERIAL FOR ALL ANALYSES : 4.9ml K-EDTA tube
All pre-analytical information on: www.chuv.ch/analyses
In gray italic: in development, please contact the laboratory for further details.

In parentheses, the quantification of the mentioned metabolite(s) or the pharmacokinetic booster is provided (at no cost).

(1) Availability of clinical interpretation (by decreasing relevance):

A. TDM is well established and reference intervals are defined. **B.** TDM can be performed and reference intervals are available. **C.** There is no clear target interval and TDM interpretation is limited to pharmacokinetic plausibility. **D.** Benefit of TDM needs to be established. Limited pharmacokinetic data. Result provided without clinical interpretation.

(2) Results provided at no cost if used as a PI-booster. Courtesy of the laboratory.

(3) Development of the quantification of new generation anti-HCV drugs (Elbasvir, Glecaprevir, Grazoprevir, Ledipasvir, Pibrentasvir, Voxilaprevir): on demand

(4) The patient should be informed that the analyse is not within LA list and generally not covered by health insurance, see link below

[OFSP Analysenlist](#)